- Significantly reduced lung inflammation: lower neutrophil counts and decreased levels of TNF-α, IL-1β, IL-6 in BALF and lung tissue (21, 46) - Less alveolar edema and damage: decreased lung wet-to-dry ratio and histological injury score compared to untreated ARDS (23, 46) - Improved pulmonary function: partial restoration of oxygenation and compliance, as well as doubled survival vs. controls (60 vs. 30%) in severe ARDS (21). The gene discussed is IL1B; the disease is acute respiratory distress syndrome.